Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04682964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bacteriophage Therapy in Tonsillitis

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 21, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv9
  2. Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Study completion date: Dec 31, 2024 to Dec 31, 2028
    v8
  3. Re-verified, no change to tracked fieldsv7
  4. Primary completion date: Aug 31, 2022 to Dec 31, 2024v6
  5. Primary completion date: Jun 30, 2022 to Aug 31, 2022v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Jun 30, 2021 to Jun 30, 2022
    • Study completion date: Dec 31, 2022 to Dec 31, 2024
    v4
  2. Primary completion date: Dec 31, 2020 to Jun 30, 2021
    • Study completion date: Jun 1, 2021 to Dec 31, 2022
    v3
  3. Eligibility criteria expanded, about 30 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil mucosa. A total of 5 ml of PCL was inhaled for 10 minutes every 5 days. The drug causes the lysis of certain bacteria, including staphylococcus, enterococcus, streptococcus, enteropathogenic E. coli, Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae and Klebsiella oxytoca. The choice of this drug was based on bacteriological studies.
Trial Details
NCT Number NCT04682964
Lead Sponsor Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan
Conditions
(from sponsor)		 Acute Tonsillitis
Enrollment 128 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov